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Abstract
Introduction Fibroblast growth factor 2 (FGF2) is a growth
factor that is immediately released after cartilage injury and plays
a pivotal role in cartilage homeostasis. In human adult articular
cartilage, FGF2 mediates anti-anabolic and potentially catabolic
effects via the suppression of proteoglycan (PG) production
along with the upregulation of matrix-degrading enzyme activity.
The aim of the present study was to determine the biological
effects of FGF2 in spine disc cells and to elucidate the complex
biochemical pathways utilized by FGF2 in bovine intervertebral
disc (IVD) cells in an attempt to further understand the
pathophysiologic processes involved in disc degeneration.
Methods We studied the effect of FGF2 on IVD tissue
homeostasis by assessing MMP-13 expression (potent matrix-
degrading enzyme), PG accumulation, and PG synthesis in the
bovine spine IVD, as well as evaluating whether FGF2
counteracts known anabolic factors such as BMP7. To
understand the molecular mechanisms by which FGF2
antagonizes BMP7 activity, we also investigated the signaling
pathways utilized by FGF2 in bovine disc tissue.
Results The primary receptor expressed in bovine nucleus
pulposus cartilage is FGFR1, and this receptor is upregulated in
degenerative human IVD tissue compared with normal IVD
tissue. Stimulation of bovine nucleus pulposus cells cultured in
monolayer with FGF2 augmented the production of MMP-13 at
the transcriptional and translational level in a dose-dependent
manner. Stimulation of bovine nucleus pulposus cells cultured in
alginate beads for 21 days with FGF2 resulted in a dose-
dependent decrease in PG accumulation, due at least in part to
the inhibition of PG synthesis. Further studies demonstrate that
FGF2 (10 ng/ml) antagonizes BMP7-mediated acceleration of
PG production in bovine nucleus pulposus cells via the
upregulation of noggin, an inhibitor of the transforming growth
factor beta/bone morphogenetic protein signaling pathway.
Chemical inhibitor studies showed that FGF2 utilizes the
mitogen-activated protein kinase and NF-κB pathways to
upregulate noggin, serving as one potential mechanism for its
anti-anabolic effects.
Conclusion FGF2 is anti-anabolic in bovine spine disc cells,
revealing the potential of FGF2 antagonists as unique biologic
treatments for both prevention and reversal of IVD degeneration.
Introduction
Back pain is a common ailment among American adults, with
a lifetime prevalence of approximately 70% to 85% in the
United States [1]. While the etiology is largely unknown, the
pathological degeneration of the intervertebral disc (IVD) has
been associated with chronic back pain [2,3]. At present, the
current treatments for back pain are mainly symptomatic or
involve surgical procedures that ablate the disc, but most
strategies make no attempt to interfere with early biochemical
and pathophysiologic processes involved in disc degenera-
tion. Elucidation of the contributory metabolic pathways at play
would therefore enable us to focus on more specific treatment
regimens in the future.
Structurally, the IVD consists of tough outer rings, collectively
termed the annulus fibrosus (AF), and a gelatinous inner core,
ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; AF = annulus fibrosus; BMP = bone morphogenetic protein; CM = cell-
associated matrix; DMEM = Dulbecco's modified Eagle's medium; DMMB = dimethylethylene blue; ECM = extracellular matrix; FGF2 = fibroblast 
growth factor 2; FGFR = fibroblast growth factor receptor; IL = interleukin; IVD = intervertebral disc; MMP = matrix metalloprotease; NF = nuclear 
factor; NP = nucleus pulposus; PCR = polymerase chain reaction; PG = proteoglycan; RT = reverse transcriptase; TGFβ = transforming growth 
factor beta.Arthritis Research & Therapy    Vol 10 No 2    Li et al.
Page 2 of 12
(page number not for citation purposes)
the nucleus pulposus (NP). This unique structure has both
shock-absorbing properties and the ability to resist deforma-
tion upon mechanical loading. The AF is composed mainly of
collagen secreted by disc cells, while the NP is largely com-
posed of proteoglycans (PGs), principally aggrecan. It has
been suggested that the degenerative process begins in the
NP and is associated with the progressive loss of PGs [2].
Disc cells residing in both the AF and NP actively regulate
matrix homeostasis through activities modulated by a variety of
stimuli, including cytokines and growth factors acting in a
paracrine and/or autocrine fashion. The cells in the normal
adult IVD maintain the matrix in which they reside at a steady
state. Degeneration of the IVD may result from an imbalance
between the anabolic and catabolic processes and loss of this
steady-state metabolism [4]. IVD damage caused by mechan-
ical injury, inflammation, or aging may change the structure of
the IVD, shifting IVD homeostasis and disc cell-mediated gene
expression in favor of a procatabolic state. Evidence shows
that matrix metalloproteases (for example, MMP-13 – other-
wise known as collagenase 3) and aggrecanases (ADAMTS4
and ADAMTS5) – enzymes strongly upregulated by proinflam-
matory cytokines – may have critical pathogenic roles in the
extracellular matrix (ECM) degradation that characterizes the
degeneration of the IVD [5]. In particular, MMP-13 has been
shown to act as a PG-degrading enzyme in addition to assist-
ing in collagen degradation, and thus may play a dual role in
IVD degeneration [6].
Regenerative medicine is aimed at regulating the metabolism
of IVD cells to achieve biological regeneration that will have
more permanent therapeutic benefits than synthetic or metallic
implants. Anabolic regulators of IVD homeostasis include
polypeptide growth factors, such as insulin-like growth factor
1, transforming growth factor beta (TGFβ) and the bone mor-
phogenetic proteins (BMPs) [7]. In particular, numerous
reports have implied the anabolic effect mediated by BMP7
(otherwise known as osteogenic protein-1) on cartilage regen-
eration in both articular joints [8] and spine discs in vitro
[9,10]. Catabolic regulators of IVD homeostasis, on the other
hand, include proinflammatory cytokines and growth factors
such as IL-1 [5,11,12] – and potentially fibroblast growth fac-
tor 2 (FGF2) (otherwise known as basic fibroblast growth fac-
tor) [13] – both of which have been implicated in the
degeneration of the IVD. An upregulation of anabolic factors
coupled with a downregulation of catabolic factors may poten-
tially induce cartilage regeneration.
In cartilage, FGF2 is produced by chondrocytes, is stored in
the ECM, and is immediately released from the ECM upon car-
tilage injury [14]. We recently reported significant upregula-
tion of FGF2 and its cognate receptor, fibroblast growth factor
receptor type I (FGFR1), in arthritic articular cartilage com-
pared with normal cartilage [13]. In human adult articular car-
tilage, FGF2 stimulates cartilage-degrading enzyme
expression, inhibits PG accumulation and synthesis, and
antagonizes the anabolic activity of insulin-like growth factor 1
and BMP7, suggesting that FGF2 plays a principal pathophys-
iological role in articular cartilage [8,13,15,16]. In the IVD,
Peng and colleagues demonstrated highly upregulated FGF2
and FGFR1 in painful degenerated human spine disc cells
compared with normal cells [17]. Further immunohistologic
studies have demonstrated the presence of FGF2 in human
herniated IVD tissue [18,19] and in injured AF tissue in adult
merinos [20]. While these findings demonstrate the localiza-
tion and/or expression of FGF2 in IVD tissue, however, the
function and biological effects mediated by FGF2 in spine
discs have yet to be assessed.
In the current study, we determined the role of FGF2 in the IVD
using bovine disc cells. Specifically, we studied the effect of
FGF2 on IVD homeostasis by assessing MMP-13 production,
PG accumulation, and PG synthesis in the bovine spine, as
well as evaluating whether FGF2 counteracts known anabolic
factors such as BMP7. Our results may provide important new
information on spine disc metabolism mediated by FGF2 rela-
tive to the understanding of IVD degeneration as one mecha-
nism of low back pain.
Materials and methods
Nucleus pulposus and annulus fibrosus cell isolation 
and culture
Human lumbar IVDs were obtained from cadaveric donor
spines (Gift of Hope) from June 2004 to June 2005. The gross
morphology of each disc was graded by the Thompson grad-
ing scheme [21] after magnetic resonance imaging T2 imag-
ing. NP tissue from normal discs (grade 0 to 2) and from
degenerative discs (grade 3 to 5) was separated from the AF
tissue. Cells were released by enzymatic digestion, as previ-
ously described [22], and were analyzed using RT-PCR as
described below. The experiments were repeated twice, using
discs from two cadaveric spines.
Bovine IVD tissue was obtained from bovine tails of young
adult animals (15 to 18 months old, purchased from a local
slaughterhouse). Coccygeal discs were opened en bloc, and
the NP and AF portions of each disc were separated. The cells
were released by enzymatic digestion in DMEM/Ham's F-12
(1:1) culture medium with sequential treatments of 0.2% pro-
nase and 0.025% collagenase P, as previously described
[23]. Alginate beads and monolayers were made for long-term
and short-term analysis, respectively.
For alginate bead cultures, isolated NP cells and AF cells were
resuspended in 1.2% alginate, and beads were formed by
dropwise addition into a CaCl2  solution, as previously
described [24]. Briefly, beads were cultured at eight beads
per well in 24-well plates in 1 ml/well DMEM/Ham's F-12
medium (1/1) supplemented with 1% mini-insulin–transferrin–
selenium [23,25]. Cells were treated with 0.1, 0.5, 1, 5, andAvailable online http://arthritis-research.com/content/10/2/R48
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10 ng/ml FGF2 (NCI, Bethesda, MD, USA), 1 ng/ml IL-1β
(Amgen, Thousand Oaks, CA, USA) for catabolic control, or
100 ng/ml BMP7 (Stryker Biotech, Hopkinton, MA, USA) for
anabolic control. Triplicate wells were used for each condition.
Media was changed every other day for a 21-day period before
dimethylethylene blue (DMMB) analysis.
For monolayer cultures, isolated NP cells were counted and
plated at 8 × 105 cells/cm2 as previously described [8,13]. For
supernatant analysis, cells were treated with FGF2 (0, 0.5, 5,
and 10 ng/ml) or with FGF18 (10 ng/ml; PeproTech, Rocky
Hill, NJ, USA), and the supernatant was removed 24 hours
after the addition of treatments and subjected to immunoblot-
ting with anti-MMP-13 antibody, which can recognize the pro-
form and activated form of MMP-13 (R&D Systems, Minneap-
olis, MN, USA). For gene expression analysis, NP cells har-
vested after treatment with FGF2 or FGF18 were analyzed for
MMP-13, ADAMTS4, and ADAMTS5 mRNA expression using
RT-PCR, as described below. In addition, NP cells cultured in
monolayer were treated with FGF2 for 24 hours in the pres-
ence of ERK inhibitor (PD98059, 25 μM; Calbiochem, Gibbs-
town, NJ, USA) or IKK inhibitor (Wedelolactone, 2.5 μM;
Calbiochem), and were subjected to RT-PCR for analysis of
noggin (an inhibitor of TGFβ/bone morphogenetic protein sig-
naling pathway) gene expression. Control NP cells (no treat-
ment) were analyzed for FGFR1 to FGFR4 mRNA expression.
Immunoblotting
The total protein concentrations of media were determined by
a bicinchoninic acid protein assay (Pierce, Rockford, IL, USA).
In each case, an equal amount of protein was resolved by 10%
SDS-polyacrylamide gels and transferred to nitrocellulose
membrane for immunoblot analyses as described previously
[13]. Immunoreactivity was visualized using the ECL system
(Amersham Biosciences, Piscataway, NJ, USA) and the Signal
Visual Enhancer system (Pierce), which magnifies the signal.
Reverse transcription and real-time polymerase chain 
reaction
Total cellular RNA was isolated using the Trizol reagent (Invit-
rogen, Carlsbad, CA, USA) following the instructions provided
by the manufacturer. Reverse transcription was carried out
with 1 μg total cellular RNA using the ThermoScript™ RT-PCR
system (Invitrogen) for first-strand cDNA synthesis in 50 μg
reaction volume.
For semiquantitative PCR, each reverse transcription sample
was assessed for glyceraldehyde 3-phosphate dehydroge-
nase cDNA. The cDNA was amplified by PCR using 24 to 32
cycles of 95°C for 30 seconds, 55°C to 60°C for 30 seconds,
and 72°C for 30 seconds in the presence of Taq polymerase
(Invitrogen), 50 pmol sense and antisense primers. PCR prod-
ucts were resolved on 1.5% agarose gels and were visualized
by staining with ethidium bromide and UV transillumination.
Integrated density values for the genes in question were nor-
malized to the glyceraldehyde 3-phosphate dehydrogenase
values to yield a semiquantitative assessment.
For real-time PCR the cDNA was amplified using the MyiQ
Real-Time PCR Detection System (Bio-Rad, Hercules, CA,
USA). The reverse transcription product was subjected to
real-time PCR in a 20 μl total reaction mixture containing 10 μl
Bio-Rad iQ™ SYBR Green supermix (Bio-Rad), 1 μl of 10 μM
sense and antisense primers, and 1 μl template cDNA. A
threshold cycle (CT value) was obtained from each amplifica-
tion curve using iQ5 Optical System Software provided by the
manufacturer (Bio-Rad). Relative mRNA expression was deter-
mined using the ΔΔCT method, as detailed by manufacturer
guidelines (Bio-Rad). Glyceraldehyde 3-phosphate dehydro-
genase was used as the internal control in the reaction for nor-
malization. The primer sequences and their conditions for use
are summarized in Table 1.
Dimethylethylene blue assay for proteoglycan 
production and DNA assay for cell numbers
At the end of the 21-day alginate culture period the medium
was removed, and the alginate beads were collected and
processed for PG assays using the DMMB binding method, as
previously described [25]. The cell-associated matrix (CM)
was separated from the further-removed matrix, and PG accu-
mulation per cell in the CM was quantified [25]. Cell numbers
were determined by assay of total DNA in the cell pellets using
PicoGreen (Molecular Probes, Carlsbad, CA, USA), as previ-
ously described [23].
[35S]-Sulfate incorporation into newly synthesized 
proteoglycans
The same labeling protocol was used for all cultures. On day
7 of culture in alginate, the medium was removed and replaced
by fresh medium. One hour later, this medium was replaced
with fresh medium containing [35S]-sulfate at 20 μCi/ml
(Amersham Corp, Arlington Heights, IL, USA). After incubation
for 4 hours, the labeling medium was removed and the beads
were rinsed twice in cold 1.5 mM SO4 wash media. Beads
were dissolved to separate out the CM and were digested
with papain (20 μg/ml in 0.1 M sodium acetate, 0.05 M ethyl-
enediamine tetraacetic acid, pH 5.53) at 60°C for 16 hours.
Sulfate incorporation into PGs was measured using the Alcian
blue precipitation method [26]. All samples were analyzed in
duplicate and were normalized for DNA content using
Hoechst 33258 as previously described [26].
Particle exclusion assay for matrix assessment
The cells with their pericellular matrix were visualized using the
particle exclusion assay, as previously described [24,27].
Briefly, after day 21 of culture in alginate, the beads were sol-
ubilized with sodium citrate. The cells were pelleted by centrif-
ugation, resuspended in DMEM, and then placed in the
bottom of a multiwell plate. The cells were allowed to settle
and attach to the plates for 6 to 12 hours, and formalin-fixedArthritis Research & Therapy    Vol 10 No 2    Li et al.
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erythrocytes were then added and allowed to settle for 10 to
15 minutes. Cells were then observed and photographed with
an inverted phase-contrast microscope (Nikon, Melville, NY,
USA).
Statistical analysis
Analysis of variance was performed using StatView 5.0 soft-
ware (SAS Institute, Cary, NC, USA). P < 0.05 was consid-
ered significant.
Results
Comparison of endogenous gene expression by cells 
from normal and degenerative human IVD
Fresh human NP tissue from normal IVD cells (grades 0 to 2)
and degenerative IVD cells (after surgery) were subjected to
total RNA preparation followed by semiquantitative RT-PCR
using human specific primer sets. Our RT-PCR results demon-
strated that the expression levels of mRNA for FGF2 and its
cognate receptor FGFR1, as well as those for matrix-degrad-
ing enzymes MMP-13 and ADAMTS5 (also known as aggre-
canase 2), are highly upregulated in degenerative human NP
cells. There was no significant difference in the expression of
mRNA for glyceraldehyde 3-phosphate dehydrogenase, an
internal control, by the cells from degenerative and normal IVD
(Figure 1). These results suggest that FGF2 and its receptor
FGFR1, along with specific matrix-degrading enzymes, may
play a pathogenic role in degenerative processes that accom-
pany the loss of IVD matrix homeostasis.
FGFR1 expression is upregulated in normal bovine 
nucleus pulposus tissue
The biological activity of FGF2 is mediated through extracellu-
lar binding to its high-affinity cell surface tyrosine kinase recep-
tors (FGFR1 to FRFR4) [28,29]. In our laboratory, we have
previously found that FGFR1 and FGFR3 are highly expressed
relative to FGFR2 and FGFR4 in normal human adult articular
chondrocytes using flow cytometry analysis with antibodies to
FGFR1 to FGFR4 (human knee cartilage; Muddasani P, Zhao
LJ, Im HJ, et al, unpublished data). We therefore sought to
determine the primary receptor expressed in bovine NP tissue.
Table 1
Primer sequences for RT-PCR
Gene Primer sequence (forward/reverse) (5' to 3') Size 
(base pairs)
Annealing 
temperature (°C)
Reference accession 
number
h-FGFR1 AAC CCC AGC CAC AAC, CCA
AAG CTG GGC TGG GTG TCG
687 60 EMBL: NM_015850.2
h-FGF2 GAG AAG AGC GAC CCT CAC A
TAG CTT TCT GCC CAG GTC C
278 58 EMBL: NM_002006.3
h-ADAMTS5 CCC TCT TCC CTG TGC AGT AG
CTA CGA TGC CAC CCA GCA G
363 58 EMBL: NM_007038.2
h-MMP-13 GGC TCC GAG AAA TGC AGT CTT TCT T
ATC AAA TGG GTA GAA GTC GCC ATG C
338 0 EMBL: NM_007038.2
h-GAPDH GGT ATC GTG GAA GGA CTC AT
ACC ACC TGG TGC TCA GTG TA
340 55 EMBL: XR_018317.1
Bov-MMP-13 ACC CTT CCT TAT CCC TTG ATG CCA
AAA CAG CTC TGC TTC AAC CTG CTG
110 55 EMBL: NM_174389.2
Bov-ADAMTS 4 ACT GGG CTA CTA TTA CGT GGA AAA
CAC ACA CCA TGC ACT TGTCGA ACT
155 60 EMBL: BC148059.1
Bov-ADAMTS 5 ACG TGG TGT TCT CTC CAA AG
CAT ACT GCA GCT TCG AGC CA
146 55 EMBL: XM_589193.2
Bov-FGFR1 AGG TAA CAA GAA GAC AAG CGG GCA
ATG GGC CAG TAA GTG AAG ACC ACT
127 55 EMBL: XM_001255761.1
Bov-FGFR2 ATA CCT GCG TGG TGG AGA ACG ATT
TTT GCA GAC AAA CTC CAC ATC GCC
152 55 EMBL: XM_880481.2
Bov-FGFR3 GTG GCC GTG AAG ATG CTG AAA GAT
AGG CGC CTA GCA GGT TGA TAA TGT
120 55 EMBL: NM_174318.2
Bov-FGFR4 GCT GAT TGG CCG ACA CAA GAA CAT
AGC ACA CTC CAC GAT CAC GTA CAA
85 55 EMBL: XM_602166.3
Bov-noggin TCT GTA ACT TCC TCC GCA GCT TCT
AGC GAG ATC AAA GCG CTG GAG TT
88 55 EMBL: XM_582573.3
Bov-β-actin AAG AGA TCA ATG ACC TGG CAC CCA
ACT CCT GCT TGC TGA TCC ACA TCT
141 55 EMBL: BT030480.1
ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; FGF2 = fibroblast growth factor 2; FGFR = fibroblast growth factor 
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Based on real-time PCR results, we found that FGFR1, fol-
lowed respectively by FGFR2, FGFR4, and FGFR3, is the
most abundant receptor present in bovine NP tissue (Figure
2). FGFR1 was roughly 3.8 times as prevalent as FGFR3,
while FGFR2 was roughly 2.8 times as prevalent as FGFR3.
FGF2 increases the expression of cartilage-degrading 
enzymes by bovine intervertebral disc cells
Recent studies have demonstrated that FGF2 stimulates the
production of MMP-13 and pro-inflammatory cytokines in
human adult articular cartilage [13,15,16]. We therefore
tested whether FGF2 exerts similar biological activity on IVD
cells. Real-time PCR results demonstrated that treatment of
NP cells cultured in monolayer with FGF2 for 24 hours stimu-
lated MMP-13 expression in a dose-dependent manner (Fig-
ure 3a). At concentrations of 1 and 10 ng/ml FGF2, MMP-13
mRNA expression increased by a factor of two and five,
respectively, compared with control (untreated). In contrast,
coincubation of cells with FGF18 (10 ng/ml), a member of the
FGF superfamily, showed no induction of MMP-13 mRNA
expression.
Western blot analysis (Figure 3b) supported these observa-
tions on the protein level, revealing an FGF2-stimulated, dose-
dependent increase in the expression of the pro-form of MMP-
13 compared with control, coupled with no induction of MMP-
13 after stimulation with FGF18. Finally, FGF2 increased the
expression of ADAMTS4 and ADAMTS5, well-known aggre-
canases involved in PG degradation (Figure 3c).
FGF2 inhibits proteoglycan accumulation in the cell-
associated matrix
Aggrecan, a major component of PGs, is a substrate of both
aggrecanases (ADAMTS4 and ADAMTS5) and matrix metal-
loproteases, such as MMP-13 [16] – proteases whose pro-
duction is upregulated by FGF2 (Figure 3a,c). To determine
what effect FGF2 has on PG accumulation in the CM of
bovine IVD cells, NP cells encapsulated in three-dimensional
alginate beads were cultured for 21 days in the presence of
0.1 to 10 ng/ml FGF2 or 1 ng/ml IL-1β (Figure 4). After 21
days, the addition of 0.5 ng/ml FGF2 reduced the PG accu-
mulation per cell to roughly 80% of control (untreated, lane 2).
This effect was dose dependent, as higher concentrations of
FGF2 (0.5, 1, 5 and 10 ng/ml) decreased PG accumulation
per cell (80%, 55%, 45% and <45% PG accumulation com-
pared with control, respectively). IL-1β, a cytokine with well-
documented inhibitory effects on PG synthesis, was used as
a negative control. At a concentration of 1 ng/ml FGF2, the
total amount of PG was lower than in cells treated with IL-1β1
ng/ml. These results show that FGF2 decreases PG accumu-
lation in the CM over 21 days of culture in a dose-dependent
manner.
FGF2-mediated reduction in proteoglycan accumulation 
in the cell-associated matrix
To determine whether the reduction in PG accumulation was
mediated by an FGF2-mediated inhibition of PG synthesis, the
incorporation of [35S]-sulfate by NP and AF cells into PGs was
quantified. The results showed that PG synthesis by both NP
cells (Figure 5a) and AF cells (Figure 5b) was indeed sup-
pressed in the presence of FGF2. When expressed per
Figure 1
Comparison of endogenous gene expression by cells from normal and  degenerative human intervertebral disc Comparison of endogenous gene expression by cells from normal 
and degenerative human intervertebral disc. Fresh human nucleus 
pulposus tissue from normal (grades 0 to 2) and degenerative (after 
surgery) intervertebral disc cells were subjected to total RNA prepara-
tion followed by semiquantitative RT-PCR using human specific primer 
sets. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
as the internal control. FGF2, fibroblast growth factor 2; FGFR, fibrob-
last growth factor receptor.
Figure 2
Fibroblast growth factor receptor 1 expression is upregulated in normal  bovine nucleus pulposus tissue Fibroblast growth factor receptor 1 expression is upregulated in 
normal bovine nucleus pulposus tissue. Nucleus pulposus cells iso-
lated from bovine intervertebral disc were cultured in a monolayer in 12-
well plates at 8 × 105 cells/cm2 for 48 hours and the total RNA was 
extracted to perform real-time RT-PCR of fibroblast growth factor 
receptor (FGFR1, FGFR2, FGFR3 and FGFR4) genes. Error bars rep-
resent three different donors in three separate experiments.Arthritis Research & Therapy    Vol 10 No 2    Li et al.
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microgram of DNA, this inhibition was found to be dose-
dependent in both cell types. IL-1β and BMP7 (a growth factor
well known for its ability to promote PG synthesis by chondro-
cytes) were used as negative control and positive control,
respectively. Interestingly, the AF cells were less responsive
than the NP cells to treatment with BMP7, a finding consistent
with that of previous studies [30]. Treatment with 100 ng/ml
BMP7 increased PG synthesis by AF cells to 152% of control,
compared with 210% of control in the case of NP cells. In
bovine NP cells, treatment with 10 ng/ml FGF2 alone signifi-
cantly inhibited PG synthesis, reducing the amount of PG syn-
thesized per cell by 40%. A similar finding was noted in the
case of AF cells. FGF2-mediated reduction in PG accumula-
tion in the CM is therefore, in part, the result of an inhibition of
proteoglycan synthesis.
FGF2 antagonizes BMP7-mediated stimulation of 
proteoglycan accumulation
Having previously shown that FGF2 has a potent antagonistic
effect on both BMP7 and insulin-like growth factor 1 in human
adult articular cartilage [15], we set out to determine whether
FGF2 exerts a similar biological impact on NP cells cultured in
the presence of BMP7. Our results indicate that FGF2 (10 ng/
ml), when present, completely abolishes the stimulation of PG
accumulation by BMP7 (100 ng/ml) (Figure 6a). In the present
study, BMP7 (100 ng/ml), when given alone, led to a 190%
increase in PG production. When FGF2 was incorporated into
the medium with BMP7, however, this anabolic effect was
abolished; in fact, PG production decreased by approximately
40% compared with control. The FGF2-mediated antagonistic
biological effect on BMP7 was further visualized using an
exclusion assay (Figure 6b). Taken together, the results sug-
gest that the response of bovine NP cells to exposure to FGF2
Figure 3
Fibroblast growth factor 2 increases the expression of cartilage-degrading enzymes by bovine intervertebral disc cells Fibroblast growth factor 2 increases the expression of cartilage-degrading enzymes by bovine intervertebral disc cells. Nucleus pulposus 
cells isolated from bovine intervertebral disc were cultured in monolayer in 12-well plates at 8 × 105 cells/cm2, and were serum-starved by changing 
the media to serum-free DMEM/F-12 with antibiotics for 24 hours before treatment. Cells were then treated with 0.1 to 10 ng/ml fibroblast growth 
factor 2 (FGF2) and 100 ng/ml fibroblast growth factor 18 (FGF18), collected after 24 hours, and the total RNA extracted to perform real-time RT-
PCR for (a) MMP-13 gene expression and (c) ADAMTS4 and ADAMTS5 gene expression. (b) Conditioned media was subjected to immunoblotting 
for the product of pro MMP-13. Error bars represent three different donors in three separate experiments.Available online http://arthritis-research.com/content/10/2/R48
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and BMP7 is very similar to that reported by Loeser and col-
leagues using human adult articular cartilage [15].
FGF2 stimulates noggin via the ERK mitogen-activated 
protein kinase and NF-κB pathways
While previous studies have examined the antagonistic rela-
tionship between FGF2 and BMP7 [15], few have defined the
molecular mechanisms or signaling cascades by which FGF2
exerts this effect. We incubated bovine NP cells in a monol-
ayer in medium containing FGF2 at different concentrations
(0.1, 1, 5 and 10 ng/ml). As IL-1β also antagonizes the matrix-
producing action of BMP7, we included it in this experimental
set as a control.
Using real-time PCR, we found that stimulation of cells with
FGF2 dose-dependently increased the expression of noggin,
a known inhibitor of TGFβ/bone morphogenetic protein [31],
presumably leading to decreased BMP7 activity (Figure 7a).
FGF2 at a concentration as low as 1 ng/ml was sufficient to
significantly increase (P < 0.05) noggin expression. Interest-
ingly, this FGF2-mediated stimulation of noggin expression
was completely neutralized upon the addition of the mitogen-
activated protein kinase ERK pathway-specific inhibitor,
decreasing the noggin level to that of the control group (Figure
7Bb). Moreover, giving an inhibitor of the NF-κB pathway (IKK
inhibitor peptide) along with FGF2 diminished the stimulatory
effect of FGF2 on noggin expression, but did not totally oblit-
erate the effect.
Our data suggest that FGF2 activation of the ERK mitogen-
activated protein kinase and NF-κB pathways are involved in
the inhibitory action of FGF2 on BMP7 signaling via activation
of noggin.
Discussion
The present study demonstrates the potent anti-anabolic
effects of FGF2 on IVD homeostasis. Stimulation with FGF2
mediated a dose-dependent upregulation of MMP-13, a signif-
icant inhibitory effect on PG accumulation and synthesis, and
Figure 4
Fibroblast growth factor 2 inhibits proteoglycan accumulation in the  cell-associated matrix Fibroblast growth factor 2 inhibits proteoglycan accumulation in 
the cell-associated matrix. Nucleus pulposus cells isolated from 
bovine intervertebral disc were cultured for 21 days in 1.2% alginate 
beads in serum-free medium with mini-insulin–transferrin–selenium 
(control) or the control medium plus 0.1 to 10 ng/ml fibroblast growth 
factor 2 (FGF2). Control medium plus 1 ng/ml IL-1β was used as a 
positive control. At the end of the culture period, the beads were dis-
solved in sodium citrate and cell pellets were separated by centrifuga-
tion. The amount of proteoglycan in the cell-associated matrix around 
the cells was measured by dimethylethylene blue assay and normalized 
to cell numbers using DNA measurement (DMMB/DNA). Samples 
were measured in triplicate and expressed as a percentage of the day 
21 control cultures. Error bars represent three different donors in three 
separate experiments.
Figure 5
Fibroblast growth factor 2 inhibits proteoglycan synthesis in the cell- associated matrix Fibroblast growth factor 2 inhibits proteoglycan synthesis in the 
cell-associated matrix. (a) Nucleus pulposus cells and (b) annulus 
fibrosus cells isolated from bovine intervertebral disc were cultured for 
7 days in 1.2% alginate in serum-free medium with mini-insulin–trans-
ferrin–selenium (control) or the control medium plus 1 and 10 ng/ml 
fibroblast growth factor 2 (FGF2), 1 ng/ml IL-1β, or 100 ng/ml BMP7. 
Proteoglycan synthesis was measured during the last 4 hours of culture 
using [35S]-sulfate incorporation and was normalized to cell numbers 
by DNA assay. Data expressed as a percentage of control for triplicate 
samples. Error bars represent the triplicate analysis of three pooled 
donors.Arthritis Research & Therapy    Vol 10 No 2    Li et al.
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the inability of BMP7 to stimulate PG production in the pres-
ence of FGF2. In addition, the chemical pathways utilized by
FGF2 to antagonize the activity of BMP7 were analyzed to
gain a better understanding of the complex interplay of growth
factors, cytokines, and enzymes in the IVD. To our knowledge,
this is the first study that demonstrates the pathophysiologic
effects of FGF2 in spine disc tissue.
Based on our DMMB results, treatment with FGF2 in alginate
culture for 21 days dose-dependently decreased the accumu-
lation of PG in NP cells. This reduction could be due to either
increased PG degradation or decreased synthesis, or due to
both. Examples of increased PG degradation include the
FGF2-stimulated, MMP-13-mediated or ADAMTS4-mediated
and ADAMTS5-mediated destruction of aggrecan. Accumu-
lated evidence has indicated that in arthritic articular cartilage
the overproduction of collagenases, in particular MMP-13, by
chondrocytes plays a central role in collagen and aggrecan
degradation [5,32-34]. We found that FGF2, MMP-13, and
ADAMTS5 were upregulated in human degenerative disc tis-
sue compared with normal discs (Figure 1), and that FGF2
Figure 6
Fibroblast growth factor 2 antagonizes BMP7-mediated stimulation of  proteoglycan accumulation in the cell-associated matrix Fibroblast growth factor 2 antagonizes BMP7-mediated stimula-
tion of proteoglycan accumulation in the cell-associated matrix. (a) 
Nucleus pulposus cells isolated from bovine intervertebral disc were 
cultured for 21 days in 1.2% alginate beads in serum-free medium with 
mini-insulin–transferrin–selenium (control) or the control medium plus 
10 ng/ml fibroblast growth factor 2 (FGF2), 100 ng/ml BMP7, or 10 
ng/ml FGF2 combined with 100 ng/ml BMP7. At the end of the culture 
period the beads were dissolved in sodium citrate, and cell pellets con-
taining the cells and their cell-associated matrix (CM) were separated 
by centrifugation. The amount of proteoglycan in the CM was measured 
by dimethylethylene blue assay and normalized to cell numbers using 
DNA measurement (DMMB/DNA). Samples were measured in tripli-
cate and expressed as a percentage of the day 21 control cultures. 
Error bars represent three different donors in three separate experi-
ments (Fig 6A). (b) Nucleus pulposus cell pericellular matrix production 
after alginate culture for 21 days in the presence or absence of FGF2, 
BMP7 or the combination of both factors was measured in an exclusion 
assay as described in Materials and methods. A representative sample 
was photographed using an inverted phase-contrast microscope. The 
CM can be seen excluding the erythrocytes from the cell plasma mem-
brane (original magnification × 400).
Figure 7
Fibroblast growth factor 2 stimulates noggin via the ERK mitogen-acti- vated protein kinase and NF-κB pathways Fibroblast growth factor 2 stimulates noggin via the ERK mitogen-
activated protein kinase and NF-κB pathways. Nucleus pulposus 
cells isolated from bovine intervertebral disc were cultured in a monol-
ayer in 12-well plates at 8 × 105 cells/cm2, and were serum-starved by 
changing the media to serum-free DMEM/F-12 with antibiotics for 24 
hours before treatment. (a) Cells were then treated with 0.1 to 10 ng/
ml fibroblast growth factor 2 (FGF2) and 1 ng/ml IL-1β. (b) Serum-
starved cells were treated with 10 ng/ml FGF2 in the presence or 
absence of the chemical inhibitors of ERK (ERKi, 25 μM) or IKK (IKKi, 
25 μM). The cells were collected after 24 hours, and total RNA was 
extracted to perform real-time RT-PCR of the noggin gene. Error bars 
represent three different donors in three separate experiments.Available online http://arthritis-research.com/content/10/2/R48
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stimulated ADAMTS4 and ADAMTS5 expression, as well as a
dose-dependent increase in MMP-13 expression (Figure 3a to
3c), in bovine NP cells. FGF2 therefore plausibly enhances
PG degradation in part through an upregulation of matrix-
degrading enzymes.
Our sulfate incorporation results, however, suggest that the
decrease in PG levels is at least in part due to decreased PG
synthesis. We demonstrated an FGF2-mediated, dose-
dependent suppression of PG synthesis as well as the inability
of BMP7 to stimulate PG production in the presence of FGF2
in bovine disc cells. We therefore suggest that FGF2 exerts a
dual effect on PG accumulation in spine discs via stimulation
of PG degradation as well as inhibition of PG synthesis.
Previous studies have demonstrated similar results in rabbit
articular chondrocytes [35,36], in human OA cartilage [37],
and in adult human articular chondrocytes [15], but this is the
first study to do so in spine tissue.
Outside the joint, FGF2 is known to stimulate angiogenesis
and, among other functions, play a role in wound repair [38-
41]. It has also been shown to be a potent mitogen [35,42,43],
and our results were consistent with this function. We found
that FGF2 significantly stimulates proliferation of both NP and
AF cells isolated from bovine tail IVD tissue (data not shown).
Of note, we observed that FGF2 at concentrations of 1 and 10
ng/ml stimulates threefold and 16-fold induction of cell prolif-
eration, respectively, compared with control (no FGF2 treat-
ment) after 7 days. At a concentration of 100 ng/ml, we found
>70-fold induction of NP cell proliferation after 21 days of
incubation in alginate beads.
The mitogenic capabilities of FGF2 have sparked controversy
over the exact role played by this growth factor in cartilage
homeostasis. Previous studies have suggested that FGF2
acts as an anabolic mediator of cartilage homeostasis due to
its mitogenic capacity, and several studies are currently using
FGF2 in scaffolds for cartilage regeneration and repair [43-51]
For example, FGF2 has been associated with a stimulation of
cell proliferation in adult bovine articular cartilage [43,45] and
in canine IVD cells [46]. Based on the results from this study
as well as previous results from our laboratory [15,16], how-
ever, we suggest that the mitogenic effect of FGF2 in both
human articular chondrocytes and bovine IVD tissue may be a
pathologic sign of degeneration rather than regeneration.
While FGF2 has already been found to substantially increase
cell proliferation in bovine spine discs [52], it failed to increase
ECM synthesis in parallel in our study, resulting in clustering of
cells with little surrounding ECM – a hallmark of arthritic
cartilage.
Further, we previously suggested that the increase in cell pro-
liferation mediated by FGF2 in human articular cartilage may
result from increased turnover of fibroblast-like cells rather
than chondrocytes, resulting in fibrocartilage formation rather
than the stronger, more durable hyaline cartilage [16]. We
suggest the same principle in the IVD, as treatment of bovine
NP cells with FGF2 stimulated an upregulation of collagen I
compared with collagen II (data not shown), resulting in a
decreased collagen II:I ratio and the formation of fibrocartilage
compared with the collagen II-rich cartilage of a healthy IVD.
Taken together, treatment of disc cells with FGF2 increases
cell proliferation and decreases ECM production, resulting in
clusters of disc cells in a fibrocartilage network similar to our
findings from human articular cartilage [15].
Tsai and colleagues recently analyzed the effects of FGF2 on
bovine NP cell growth and differentiation, and found that
FGF2 stimulated increased sulfated PG synthesis, lowered
aggrecan turnover, and lowered differentiation of the NP cell
phenotype by maintaining responsiveness to TGFβ [53]. Our
data, however, support the hypothesis that FGF2 serves pri-
marily as an anti-anabolic factor rather than a pro-anabolic fac-
tor in cartilage homeostasis. Indeed, similar to results reported
by Tsai and colleagues [53], we have found that FGF2 does
stimulate an overall increase in sulfated PG synthesis. After
normalizing these findings to cell number, however, our [35S]-
sulfate incorporation and DMMB results suggest that, per cell,
PG synthesis and total PG accumulation decreased dose
dependently after treatment with FGF2. In addition, Tsai and
colleagues reported increased gene expression of both colla-
gen I and collagen II; however, we suggest that the ratio
between type I and type II collagen may be more important
than overall levels to determine the homeostatic effect in IVD
tissue, and we have found an FGF2-mediated upregulation of
collagen I compared with collagen II (data not shown), leading
to the formation of a weak fibrocartilaginous network.
The potent mitogenic effect of FGF2 in cartilage has previ-
ously been correlated with FGF receptor activation. In the
growth plate, for example, FGFR1 and FGFR3 have significant
yet opposite roles in cartilage homeostasis. Binding of FGF2
to FGFR1 increases proliferation of chondrocytes, whereas
binding of FGF2 to FGFR3 inhibits proliferation and therefore
promotes differentiation [54-56]. The upregulation of FGFR1
with minimal expression of FGFR3 in the bovine IVD could
therefore potentially explain the potent mitogenic effects of
FGF2 in the spine disc. Interestingly, Valverde-Franco and col-
leagues found that, in the absence of signaling from FGFR3, a
compensatory increase in interaction is seen between FGF2
and FGFR1, resulting in degradative effects such as defective
articular cartilage with increased MMP-13 expression and
increased cleavage products from type II collagen and aggre-
can in mice [57].
Our studies revealed an upregulation of FGFR1 in degenera-
tive disc tissue (Figure 1), as well as an FGF2-mediated
increase of MMP-13 expression, but no FGF18-mediated
effect on MMP-13 expression (Figure 3a to 3c). These results
were similar to previous studies revealing that FGF18 acts pri-Arthritis Research & Therapy    Vol 10 No 2    Li et al.
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marily via FGFR3 in articular and growth plate cartilage
[57,58]. We therefore suggest that FGF2, but not FGF18, uti-
lizes FGFR1 to stimulate both mitogenic and anti-anabolic
events in bovine spine IVD tissue. Further studies linking path-
ogenic disc degeneration and FGF-ligand binding activity to
specific FGFRs may provide important information for under-
standing the potential role of FGFR1 in IVD homeostasis and
disc degeneration.
Other studies have suggested an important role of FGF2 in the
spontaneous resorption process of degenerative or herniated
IVD tissue via stimulation of angiogenesis and/or inflammatory
cytokines that aid in cartilage destruction [20,59,60]. Mina-
mide and colleagues used a rabbit disc sequestration-type
model to emulate IVD herniation in vivo, and found that epi-
dural injection of FGF2 stimulates increased angiogenesis,
increased speed of disc resorption, and increased the number
of inflammatory cells compared with control (saline) [59].
Based on these findings, we suggest multiple roles of FGF2 in
disc homeostasis depending on the stage of degeneration. In
normal or recently injured disc tissue, FGF2 may act as an anti-
anabolic mediator, suppressing PG synthesis and stimulating
MMP-13 expression. These same properties, however, may be
beneficial after disc herniation, stimulating degradation of her-
niated tissue and encouraging spontaneous disc resorption.
The expression and role of FGF2 in different stages of degen-
eration should be further analyzed in human disc tissue, as well
as in degenerative or herniated disc tissue, to gain a better
understanding of its pathophysiologic function at each stage.
Clinically, noggin may be a potential target for disc degenera-
tion as it is a well-known inhibitor of the anabolic TGFβ/bone
morphogenetic protein signaling pathway [31] and is
upregulated by FGF2 in bovine disc tissue (Figure 7). Our
pathway-specific inhibitor studies suggest that the ERK path-
way is necessary for noggin stimulation by FGF2, while the
NF-κB pathway (IKK) is involved in, but not necessary for, nog-
gin stimulation leading to inhibition of BMP7 activity. These
data suggest that mitogen-activated protein kinase (ERK) and
NF-κB are involved in the anti-anabolic actions of FGF2, a fac-
tor that exerts its effects via multiple pathways (Figure 8).
These results may be advantageous as pathway-specific inhib-
itors continue to gain favor as potential treatment strategies.
Unlike treatment with FGF2, the stimulation of cells with IL-1β
showed no significant increase in noggin expression, suggest-
ing that the inhibitory effects of FGF2 and IL-1β on BMP7 are
perhaps through distinct signaling pathways and biological
actions.
Conclusion
The present study suggests that the role of FGF2 can be
defined as anti-anabolic and potentially catabolic in IVD cells.
FGF2 enhances MMP-13, ADAMTS4, and ADAMTS5 expres-
sion at the transcriptional level, decreases PG synthesis, and
inhibits the anabolic activity of BMP7-mediated PG synthesis.
Moreover, it retains its mitogenic capacity in spine tissues
while decreasing ECM formation, leading to clustering of cells
often seen in arthritic states. The pathways involved are multi-
ple and complex, and further investigation should be pursued
to help gain a better understanding of the signaling cascades
governing the interactions between FGF2, MMP-13 and
BMP7.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
H-JI participated in the study design, analysis and interpreta-
tion of data, manuscript preparation, and statistical analysis.
XL participated in the study design, acquisition of data, analy-
sis and interpretation of data, manuscript preparation, and sta-
tistical analysis. HSA and FP participated in the study design,
collection of human tissue samples, analysis and interpretation
of the data. ME participated in analysis and interpretation of
the data, and manuscript preparation. EJT participated in the
study design and manuscript preparation. DKP and RKU par-
ticipated in the acquisition of tissues and helped data
generation.
Acknowledgements
The authors would like to thank Dr Koichi Masuda for providing human 
tissue samples. The present study was sponsored by contract grant 
number NIH RO1 AR053220 (H-JI), by the Arthritis National Research 
Foundation, by an Arthritis Foundation Chicago Chapter Grant, and by 
NIH AR48152 (HSA).
References
1. Andersson GB: Epidemiological features of chronic low-back
pain.  Lancet 1999, 354:581-585.
Figure 8
Schematic of the regulation of catabolic and anti-anabolic actions of  FGF2 in intervertebral disc cells Schematic of the regulation of catabolic and anti-anabolic actions 
of FGF2 in intervertebral disc cells. Fibroblast growth factor 2 
(FGF2) activates the mitogen-activated protein kinase (MAPK) and NF-
κB pathways, which upregulate both MMP-13 and noggin gene expres-
sion. The upregulation of the noggin gene inhibits the anabolic trans-
forming growth factor beta/bone morphogenetic protein signaling 
pathway, leading to decreased proteoglycan (PG) production.Available online http://arthritis-research.com/content/10/2/R48
Page 11 of 12
(page number not for citation purposes)
2. Buckwalter JA: Aging and degeneration of the human interver-
tebral disc.  Spine 1995, 20:1307-1314.
3. Freemont TJ, LeMaitre C, Watkins A, Hoyland JA: Degeneration
of intervertebral discs: current understanding of cellular and
molecular events, and implications for novel therapies.  Expert
Rev Mol Med 2001, 2001:1-10.
4. Iannone F, Lapadula G: The pathophysiology of osteoarthritis.
Aging Clin Exp Res 2003, 15:364-372.
5. Le Maitre CL, Freemont AJ, Hoyland JA: Localization of degrada-
tive enzymes and their inhibitors in the degenerate human
intervertebral disc.  J Pathol 2004, 204:47-54.
6. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ: Degradation
of cartilage aggrecan by collagenase-3 (MMP-13).  FEBS Lett
1996, 380:17-20.
7. Masuda K, Oegema TR Jr, An HS: Growth factors and treatment
of intervertebral disc degeneration.  Spine 2004,
29:2757-2769.
8. Im HJ, Pacione C, Chubinskaya S, Van Wijnen AJ, Sun Y, Loeser
RF: Inhibitory effects of insulin-like growth factor-1 and osteo-
genic protein-1 on fibronectin fragment- and interleukin-1β-
stimulated matrix metalloproteinase-13 expression in human
chondrocytes.  J Biol Chem 2003, 278:25386-25394.
9. Matsuyama A, Iwata H, Okumura N, Yoshida S, Imaizumi K, Lee Y,
Shiraishi S, Shiosaka S: Localization of basic fibroblast growth
factor-like immunoreactivity in the rat brain.  Brain Res 1992,
587:49-65.
10. Takegami K, Thonar EJ, An HS, Kamada H, Masuda K: Osteogenic
protein-1 enhances matrix replenishment by intervertebral
disc cells previously exposed to interleukin-1.  Spine 2002,
27:1318-1325.
11. Le Maitre CL, Hoyland JA, Freemont AJ: Catabolic cytokine
expression in degenerate and herniated human intervertebral
discs: IL-1β and TNFα expression profile.  Arthritis Res Ther
2007, 9:R77.
12. Shinmei M, Kikuchi T, Yamagishi M, Shimomura Y: 28The role of
interleukin-1 on proteoglycan metabolism of rabbit annulus
fibrosus cells cultured in vitro.  Spine 1988, 13:1284-1290.
13. Im HJ, Muddasani P, Natarajan V, Schmid TM, Block JA, Davis F,
van Wijnen AJ, Loeser RF: Basic fibroblast growth factor stimu-
lates matrix metalloproteinase-13 via the molecular cross-talk
between the mitogen-activated protein kinases and protein
kinase Cdelta pathways in human adult articular
chondrocytes.  J Biol Chem 2007, 282:11110-11121.
14. Vincent T, Hermansson M, Bolton M, Wait R, Saklatvala J: Basic
FGF mediates an immediate response of articular cartilage to
mechanical injury.  Proc Natl Acad Sci USA 2002,
99:8259-8264.
15. Loeser RF, Chubinskaya S, Pacione C, Im HJ: Basic fibroblast
growth factor inhibits the anabolic activity of insulin-like
growth factor 1 and osteogenic protein 1 in adult human artic-
ular chondrocytes.  Arthritis Rheum 2005, 52:3910-3917.
16. Muddasani P, Norman JC, Ellman M, van Wijnen AJ, Im HJ: Basic
fibroblast growth factor activates the MAPK and NFkappaB
pathways that converge on Elk-1 to control production of
matrix metalloproteinase-13 by human adult articular
chondrocytes.  J Biol Chem 2007, 282:31409-31421.
17. Peng B, Hao J, Hou S, Wu W, Jiang D, Fu X, Yang Y: Possible
pathogenesis of painful intervertebral disc degeneration.
Spine 2006, 31:560-566.
18. Doita M, Kanatani T, Harada T, Mizuno K: Immunohistologic
study of the ruptured intervertebral disc of the lumbar spine.
Spine 1996, 21:235-241.
19. Tolonen J, Gronblad M, Vanharanta H, Virri J, Guyer RD, Rytomaa
T, Karaharju EO: Growth factor expression in degenerated
intervertebral disc tissue. An immunohistochemical analysis
of transforming growth factor beta, fibroblast growth factor
and platelet-derived growth factor.  Eur Spine J 2006,
15:588-596.
20. Melrose J, Smith S, Little CB, Kitson J, Hwa SY, Ghosh P: Spatial
and temporal localization of transforming growth factor-beta,
fibroblast growth factor-2, and osteonectin, and identification
of cells expressing alpha-smooth muscle actin in the injured
anulus fibrosus: implications for extracellular matrix repair.
Spine 2002, 27:1756-1764.
21. Thompson JP, Pearce RH, Schechter MT, Adams ME, Tsang IK,
Bishop PB: Preliminary evaluation of a scheme for grading the
gross morphology of the human intervertebral disc.  Spine
1990, 15:411-415.
22. Patel KP, Sandy JD, Akeda K, Miyamoto K, Chujo T, An HS, Mas-
uda K: Aggrecanases and aggrecanase-generated fragments
in the human intervertebral disc at early and advanced stages
of disc degeneration.  Spine 2007, 32:2596-2603.
23. Loeser RF, Todd MD, Seely BL: Prolonged treatment of human
osteoarthritic chondrocytes with insulin-like growth factor-I
stimulates proteoglycan synthesis but not proteoglycan matrix
accumulation in alginate cultures.  J Rheumatol 2003,
30:1565-1570.
24. Hauselmann HJ, Masuda K, Hunziker EB, Neidhart M, Mok SS,
Michel BA, Thonar EJ: Adult human chondrocytes cultured in
alginate form a matrix similar to native human articular
cartilage.  Am J Physiol 1996, 271(3 Pt 1):C742-C752.
25. Gruber HE, Hoelscher GL, Leslie K, Ingram JA, Hanley EN Jr:
Three-dimensional culture of human disc cells within agarose
or a collagen sponge: assessment of proteoglycan production.
Biomaterials 2006, 27:371-376.
26. Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ, Son-
ntag WE: Reduction in the chondrocyte response to insulin-
like growth factor 1 in aging and osteoarthritis: studies in a
non-human primate model of naturally occurring disease.
Arthritis Rheum 2000, 43:2110-2120.
27. Knudson CB: Hyaluronan receptor-directed assembly of
chondrocyte pericellular matrix.  J Cell Biol 1993, 120:825-834.
28. Coughlin SR, Barr PJ, Cousens LS, Fretto LJ, Williams LT: Acidic
and basic fibroblast growth factors stimulate tyrosine kinase
activity in vivo.  J Biol Chem 1988, 263:988-993.
29. Johnson DE, Williams LT: Structural and functional diversity in
the FGF receptor multigene family.  Adv Cancer Res 1993,
60:1-41.
30. Zhang Y, An HS, Song S, Toofanfard M, Masuda K, Andersson
GB, Thonar EJ: Growth factor osteogenic protein-1: differing
effects on cells from three distinct zones in the bovine
intervertebral disc.  Am J Phys Med Rehabil 2004, 83:515-521.
31. Reinhold MI, Abe M, Kapadia RM, Liao Z, Naski MC: FGF18
represses noggin expression and is induced by calcineurin.  J
Biol Chem 2004, 279:38209-38219.
32. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin
C, Krane SM: Critical roles for collagenase-3 (Mmp13) in devel-
opment of growth plate cartilage and in endochondral
ossification.  Proc Natl Acad Sci USA 2004, 101:17192-17197.
33. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A,
Lopez-Otin C: Matrix metalloproteinase 13 (collagenase 3) in
human rheumatoid synovium.  Arthritis Rheum 1997,
40:1391-1399.
34. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum
SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression,
and type II collagenolytic activity of matrix metalloproteinase-
13 from human osteoarthritic cartilage.  J Clin Invest 1996,
97:761-768.
35. Sachs BL, Goldberg VM, Moskowitz RW, Malemud CJ: Response
of articular chondrocytes to pituitary fibroblast growth factor
(FGF).  J Cell Physiol 1982, 112:51-59.
36. Prins AP, Lipman JM, McDevitt CA, Sokoloff L: Effect of purified
growth factors on rabbit articular chondrocytes in monolayer
culture. II. Sulfated proteoglycan synthesis.  Arthritis Rheum
1982, 25:1228-1238.
37. Posever J, Phillips FM, Pottenger LA: Effects of basic fibroblast
growth factor, transforming growth factor-beta 1, insulin-like
growth factor-1, and insulin on human osteoarthritic articular
cartilage explants.  J Orthop Res 1995, 13:832-837.
38. Trippel SB: Growth factor actions on articular cartilage.  J Rheu-
matol Suppl 1995, 43:129-132.
39. Oda Y, Kagami H, Ueda M: Accelerating effects of basic fibrob-
last growth factor on wound healing of rat palatal mucosa.  J
Oral Maxillofac Surg 2004, 62:73-80.
40. Miyoshi M, Kawazoe T, Igawa HH, Tabata Y, Ikada Y, Suzuki S:
Effects of bFGF incorporated into a gelatin sheet on wound
healing.  J Biomater Sci Polym Ed 2005, 16:893-907.
41. Liu Y, Cai S, Shu XZ, Shelby J, Prestwich GD: Release of basic
fibroblast growth factor from a crosslinked glycosaminogly-
can hydrogel promotes wound healing.  Wound Repair Regen
2007, 15:245-251.Arthritis Research & Therapy    Vol 10 No 2    Li et al.
Page 12 of 12
(page number not for citation purposes)
42. Jones KL, Addison J: Pituitary fibroblast growth factor as a stim-
ulator of growth in cultured rabbit articular chondrocytes.
Endocrinology 1975, 97:359-365.
43. Osborn KD, Trippel SB, Mankin HJ: Growth factor stimulation of
adult articular cartilage.  J Orthop Res 1989, 7:35-42.
44. Cucchiarini M, Madry H, Ma C, Thurn T, Zurakowski D, Menger
MD, Kohn D, Trippel SB, Terwilliger EF: Improved tissue repair
in articular cartilage defects in vivo by rAAV-mediated overex-
pression of human fibroblast growth factor 2.  Mol Ther 2005,
12:229-238.
45. Sah RL, Chen AC, Grodzinsky AJ, Trippel SB: Differential effects
of bFGF and IGF-I on matrix metabolism in calf and adult
bovine cartilage explants.  Arch Biochem Biophys 1994,
308:137-147.
46. Thompson JP, Oegema TR Jr, Bradford DS: Stimulation of
mature canine intervertebral disc by growth factors.  Spine
1991, 16:253-260.
47. Nagano T, Yonenobu K, Miyamoto S, Tohyama M, Ono K: Distri-
bution of the basic fibroblast growth factor and its receptor
gene expression in normal and degenerated rat intervertebral
discs.  Spine 1995, 20:1972-1978.
48. Kaul G, Cucchiarini M, Arntzen D, Zurakowski D, Menger MD,
Kohn D, Trippel SB, Madry H: Local stimulation of articular car-
tilage repair by transplantation of encapsulated chondrocytes
overexpressing human fibroblast growth factor 2 (FGF-2) in
vivo.  J Gene Med 2006, 8:100-111.
49. Hiraide A, Yokoo N, Xin KQ, Okuda K, Mizukami H, Ozawa K, Saito
T: Repair of articular cartilage defect by intraarticular adminis-
tration of basic fibroblast growth factor gene, using adeno-
associated virus vector.  Hum Gene Ther 2005, 16:1413-1421.
50. Inoue A, Takahashi KA, Arai Y, Tonomura H, Sakao K, Saito M,
Fujioka M, Fujiwara H, Tabata Y, Kubo T: The therapeutic effects
of basic fibroblast growth factor contained in gelatin hydrogel
microspheres on experimental osteoarthritis in the rabbit
knee.  Arthritis Rheum 2006, 54:264-270.
51. Stewart K, Pabbruwe M, Dickinson S, Sims T, Hollander AP,
Chaudhuri JB: The effect of growth factor treatment on menis-
cal chondrocyte proliferation and differentiation on polygly-
colic acid scaffolds.  Tissue Eng 2007, 13:271-280.
52. Pratsinis H, Kletsas D: PDGF, bFGF and IGF-I stimulate the pro-
liferation of intervertebral disc cells in vitro via the activation of
the ERK and Akt signaling pathways.  Eur Spine J 2007,
16:1858-1866.
53. Tsai TT, Guttapalli A, Oguz E, Chen LH, Vaccaro AR, Albert TJ,
Shapiro IM, Risbud MV: Fibroblast growth factor-2 maintains
the differentiation potential of nucleus pulposus cells in vitro:
implications for cell-based transplantation therapy.  Spine
2007, 32:495-502.
54. Kilkenny DM, Hill DJ: Perinuclear localization of an intracellular
binding protein related to the fibroblast growth factor (FGF)
receptor 1 is temporally associated with the nuclear trafficking
of FGF-2 in proliferating epiphyseal growth plate
chondrocytes.  Endocrinology 1996, 137:5078-5089.
55. Wang Q, Green RP, Zhao G, Ornitz DM: Differential regulation
of endochondral bone growth and joint development by
FGFR1 and FGFR3 tyrosine kinase domains.  Development
2001, 128:3867-3876.
56. Weksler NB, Lunstrum GP, Reid ES, Horton WA: Differential
effects of fibroblast growth factor (FGF) 9 and FGF2 on prolif-
eration, differentiation and terminal differentiation of chondro-
cytic cells in vitro.  Biochem J 1999, 342(Pt 3):677-682.
57. Valverde-Franco G, Binette JS, Li W, Wang H, Chai S, Laflamme
F, Tran-Khanh N, Quenneville E, Meijers T, Poole AR, Mort JS,
Buschmann MD, Henderson JE: Defects in articular cartilage
metabolism and early arthritis in fibroblast growth factor
receptor 3 deficient mice.  Hum Mol Genet 2006,
15:1783-1792.
58. Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G,
Buschmann MD, Henderson JE: Fibroblast growth factor (FGF)
18 signals through FGF receptor 3 to promote
chondrogenesis.  J Biol Chem 2005, 280:20509-20515.
59. Minamide A, Hashizume H, Yoshida M, Kawakami M, Hayashi N,
Tamaki T: Effects of basic fibroblast growth factor on sponta-
neous resorption of herniated intervertebral discs. An experi-
mental study in the rabbit.  Spine 1999, 24:940-945.
60. Walsh AJ, Bradford DS, Lotz JC: In vivo growth factor treatment
of degenerated intervertebral discs.  Spine 2004, 29:156-163.